Rapamycin
Sirolimus
Rapamycin (Sirolimus) is a longevity & bioregulators research compound. mTOR inhibitor — intermittent inhibition of mTORC1 upregulates autophagy and mimics caloric restriction; the most-studied longevity small molecule.
Rapamycin quick facts
| Reported research dose | 1mg-6mg |
| Route | Oral |
| Frequency | 1x Weekly |
| Half-life | ~60 hrs |
| Forms | Oral |
| Evidence level | FDA-approved (transplant); longevity off-label |
Weekly/pulsed, NEVER daily for longevity — the schedule is the whole game. Overdo it and you're just immunosuppressed.
How Rapamycin works
mTOR inhibitor — intermittent inhibition of mTORC1 upregulates autophagy and mimics caloric restriction; the most-studied longevity small molecule.
Proposed benefits
Researched for mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
✅ Clinically validated
- FDA-approved since 1999 as sirolimus, for prevention of kidney transplant rejection, with extensive trial data at immunosuppressive doses. Also approved for lymphangioleiomyomatosis and used on drug-eluting coronary stents.
- The longevity use is off-label and not proven in humans. The strongest human hint is a Novartis trial of the rapalog everolimus in adults over 65, which reported improved influenza vaccine response — an immune-ageing endpoint rather than a lifespan one. Trials in dogs (the Dog Aging Project) and human pilots are ongoing.
📊 Correlative data
- The most-replicated lifespan result in mammalian biology — the NIA Interventions Testing Program extended median lifespan in mice across multiple independent sites, including when started in old age.
- Human off-label use for longevity runs at intermittent weekly dosing rather than daily, on the reasoning that it separates the mTORC1 effect from the mTORC2 effects that cause the transplant-dose side effects. That separation is a hypothesis, not a demonstrated fact — the dosing has never been validated against any hard human endpoint.
🧪 Theoretical / extrapolated
- Inhibits mTORC1 by binding FKBP12. mTOR is the cell's nutrient sensor: when it is active, the cell builds; when it is inhibited, the cell switches to autophagy — recycling damaged proteins and organelles. Accumulated cellular damage is a central ageing mechanism, so this is the most mechanistically coherent longevity target that exists.
- The predicted downsides come from the same mechanism. Suppressing building means suppressing immune cell proliferation, wound healing and muscle protein synthesis — which is why it causes immunosuppression, impaired healing, mouth ulcers and dyslipidaemia at chronic doses.
- Chronic dosing also inhibits mTORC2, which drives the insulin resistance seen in transplant patients. The whole case for intermittent dosing rests on avoiding that, and the whole uncertainty rests on nobody having proven it does.
These tiers tell you how much human evidence exists — not how well something works. This is the research space, and most of what’s in here is new rather than disproven. Something sitting at “theoretical” usually means nobody has funded the trial, not that the trial was run and failed.
The trap runs the other way too: something can be clinically validated and still do very little for you specifically. A statistically significant result in a study population is not a promise about your body.
- ✅ Clinically validated — human randomised trials or meta-analyses support it. The strongest footing available.
- 📊 Correlative — observational or epidemiological data. Suggestive, and genuinely useful for direction, but it cannot establish cause.
- 🧪 Theoretical / mechanistic — the mechanism is understood and often demonstrated in cells or animals, and the human trial doesn’t exist yet. Unproven is not the same as ineffective. Plenty of what’s standard practice today sat here five years ago.
✗ is a safety flag, not a grade. Where you see it, the concern is harm — not a disappointing trial. A compound tested for one purpose and found not to help there can still be worth studying somewhere else, so a negative result never gets rendered as a cross. It sits alongside the tier, because something can be both well-studied and genuinely risky.
My job is to tell you which one you’re looking at, and let you make the call. Grading something low isn’t me dismissing it — it’s me refusing to oversell it. This is the research space, and being able to reason forward from a mechanism matters as much as waiting for the trial.
Rapamycin — safety, predicted from mechanism
Much of this compound class has never been through a human safety trial. Rather than say nothing — or print a generic warning — this is what its known mechanism predicts could go wrong, and what you can do about it. Predictions are labelled as predictions.
What the mechanism predicts
Derived from what this molecule does, not from a trial.
- These are short peptide fragments of organ extracts, and the honest starting point is that the mechanism itself is not established in a way that lets anyone predict harm precisely. The proposal is gene-regulatory — short peptides binding DNA and modulating transcription in a tissue-specific way. If that is what they do, the theoretical concern is influencing transcription in tissue you were not aiming at.
- In practice the doses are tiny, the peptides are short, and they are degraded quickly — which is also the argument that they may do very little at all. Those two possibilities are the same uncertainty viewed from opposite ends, and you should hold both.
What has actually been reported
- Decades of Russian clinical use with a strikingly clean tolerability record — injection-site reactions and little else reported.
- That record comes almost entirely from one research school, is largely unreplicated outside it, and safety data from a group with an interest in the outcome is worth less than the same data from a sceptic. This is not an accusation; it is how evidence weighting works.
How to reduce the risk
Each of these follows from the same mechanism as the prediction.
- Follow the course printed on the label rather than running continuously. These are the one class in the Vault where a duration is STATED rather than inferred, and it is typically 10–20 days repeated a few times a year. Read the box.
- Run one at a time. They are cheap and it is tempting to stack six. If something changes, a stack of six tells you nothing about which one did it — and given the evidence base, attribution is the entire value of your own experiment.
- Decide your endpoint before you start, and make it a marker or a measurable symptom rather than a feeling. With a compound class this under-evidenced, an unfalsifiable endpoint means you will conclude it worked no matter what happened.
- Buy from a source that publishes third-party testing. Where the molecule itself is uncertain, identity and purity are the only variables you can actually control.
What it does to your bloodwork
A fact about the assay, not a guess about the drug.
- Test the ORGAN, not the peptide. A thymic peptide is judged on immune markers, a pineal one on sleep and IGF-1, a vascular one on lipids and inflammatory markers. There is no assay for the compound itself.
Don't run this if
- Pregnancy — not because of a specific finding, but because nobody has studied it and the mechanism claim is transcriptional.
- Active malignancy, on the same reasoning as any tissue-growth signal: unproven, mechanistically arguable, and not worth finding out.
The honest unknown
- Essentially everything a sceptic would want: independent replication, pharmacokinetics, and whether the oral forms survive digestion at all. Unproven is not the same as ineffective — but here it is a large unproven.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Where to get Rapamycin
Buy Rapamycin at AlgoRx →Rapamycin — interference & stacking
Predicted from mechanism, not from an interaction study. There are no trials of these combinations — what follows is what the biology implies, so treat it as a reason to watch something, not as a finding.
What Rapamycin moves on your bloodwork
These are the markers this compound is expected to move, and which direction. Knowing that in advance is mostly about NOT panicking: some of these moving is the compound working.
- hs-CRP (High-Sensitivity C-Reactive Protein) — ↓ expected to fall
Where these work, systemic inflammation is the plausible readout.
What to do: hs-CRP is cheap and moves. Baseline and 12 weeks. - HbA1c (Hemoglobin A1c) — ↓ expected to fall
Improved mitochondrial and metabolic function should show here if the effect is real at all.
What to do: The honest use of these markers is as a falsification test: if nothing moves in 12 weeks, the compound is not doing much for you. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Liver and kidney function — the standard baseline for anything run long term.
What to do: Twice a year is enough on a stable protocol.
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Get the complete breakdown for Rapamycin — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →This class is where honest expectation-setting matters most: the markers above are how you find out whether anything happened, and for most of these compounds that question is genuinely open.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
Get the complete breakdown for Rapamycin — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →Bloodwork to run alongside Rapamycin
Run these before you start, and again after 8–12 weeks. A baseline you didn’t take is one you can never go back for.
| Marker | What it’s watching for |
|---|---|
| Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) | Raises triglycerides and LDL in a large share of users. Expect it |
| HbA1c (Hemoglobin A1c) | Impairs glucose tolerance — the trade-off nobody mentions |
| Complete Blood Count (CBC) with Differential | Immunosuppressant. Watch white cells and platelets |
| Comprehensive Metabolic Panel (CMP) | Liver, kidney and electrolytes |
| Sirolimus (Rapamycin), Whole Blood | Rapamycin IS sirolimus — trough levels are how it's actually dosed |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 102 markers A–Z
Rapamycin — frequently asked questions
What is Rapamycin?
Rapamycin (Sirolimus) is a longevity & bioregulators research compound. mTOR inhibitor — intermittent inhibition of mTORC1 upregulates autophagy and mimics caloric restriction; the most-studied longevity small molecule.
Is the full Rapamycin protocol on this page?
The reported research dose is on this page, along with how Rapamycin works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside the Academy.
What is the half-life of Rapamycin?
Rapamycin has an approximate half-life of ~60 hrs, which is part of what determines how often it's dosed.
What's the evidence behind Rapamycin?
Current evidence level: FDA-approved (transplant); longevity off-label. Rapamycin is offered for research purposes only and is not an approved medicine.
Want Coach Cam's exact Rapamycin protocol?
Dosing schedules, stacking, cycle timing and my personal notes live inside the Academy — plus the full interactive Vault of 237 compounds & 350 supplements.
Join the Academy — $10/mo →What Rapamycin is used for
Rapamycin appears under 1 goal in the Vault’s goal router, grouped by the mechanism it works through rather than by how much trial evidence exists. Each link opens that pathway in full, with the alternatives beside it and the bloodwork that tests it.